Virtus ETF Advisers’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,761
| Closed | -$68K | – | 571 |
|
|
2024
Q4 | $68K | Sell |
1,761
-919
| -34% | -$35.5K | 0.03% | 396 |
|
|
2024
Q3 | $121K | Buy |
2,680
+45
| +2% | +$2.03K | 0.06% | 352 |
|
|
2024
Q2 | $91.3K | Sell |
2,635
-1,540
| -37% | -$53.4K | 0.04% | 353 |
|
|
2024
Q1 | $121K | Sell |
4,175
-282
| -6% | -$8.16K | 0.06% | 346 |
|
|
2023
Q4 | $102K | Buy |
4,457
+1,017
| +30% | +$23.3K | 0.06% | 349 |
|
|
2023
Q3 | $57.4K | Sell |
3,440
-346
| -9% | -$5.77K | 0.03% | 407 |
|
|
2023
Q2 | $105K | Sell |
3,786
-6,500
| -63% | -$180K | 0.06% | 360 |
|
|
2023
Q1 | $237K | Sell |
10,286
-3,949
| -28% | -$90.8K | 0.13% | 294 |
|
|
2022
Q4 | $155K | Sell |
14,235
-2
| -0% | -$22 | 0.08% | 335 |
|
|
2022
Q3 | $120K | Buy |
14,237
+108
| +0.8% | +$910 | 0.05% | 399 |
|
|
2022
Q2 | $112K | Buy |
14,129
+8,913
| +171% | +$70.7K | 0.04% | 402 |
|
|
2022
Q1 | $124K | Sell |
5,216
-305
| -6% | -$7.25K | 0.06% | 258 |
|
|
2021
Q4 | $189K | Buy |
5,521
+351
| +7% | +$12K | 0.07% | 232 |
|
|
2021
Q3 | $92K | Sell |
5,170
-271
| -5% | -$4.82K | 0.04% | 386 |
|
|
2021
Q2 | $244K | Sell |
5,441
-8,905
| -62% | -$399K | 0.1% | 218 |
|
|
2021
Q1 | $372K | Buy |
14,346
+244
| +2% | +$6.33K | 0.16% | 194 |
|
|
2020
Q4 | $284K | Sell |
14,102
-4,946
| -26% | -$99.6K | 0.12% | 238 |
|
|
2020
Q3 | $372K | Sell |
19,048
-2,591
| -12% | -$50.6K | 0.2% | 177 |
|
|
2020
Q2 | $382K | Buy |
+21,639
| New | +$382K | 0.18% | 218 |
|